Bayer raises peak sales forecast for new drugs


  • Business
  • Wednesday, 21 Sep 2016

BERLIN: Bayer AG raised its peak sales forecast for its biggest new drugs, signaling optimism for its pharmaceutical unit even as the German conglomerate spends US$66bil to buy US seeds giant Monsanto Co.

A portfolio of five new medicines including anti-clot drug Xarelto and eye medicine Eylea could generate more than 10 billion euros (US$11.2bil) in annual revenue, up from a previous estimate of at least 7.5 billion euros, the Leverkusen-based health-care and crop-science company said in a statement yesterday. Top-seller Xarelto alone is likely to generate more than 5 billion euros a year in sales at its peak.

Crop sciences will probably replace healthcare as Bayer’s biggest business after the Monsanto deal is completed by the end of next year. Funded with a combination of debt and equity, the deal will leave the company little scope for acquisitions to boost its pharmaceuticals business. Bayer emphasized the potential of drugs it already has to drive growth beyond Xarelto, which loses patent protection in 2024.

“We are very confident about our pharmaceuticals business,” chief executive officer Werner Baumann said in the statement. He highlighted the growth potential in Bayer’s pipeline of experimental drugs, saying six medicines currently being tested could generate at least 6 billion euros in annual sales.

Bayer said it’s aiming for average annual sales growth of about 6% for its prescription-drug unit by the end of 2018 with a profit margin of 32% to 34% of revenue that year while over-the-counter drug sales will grow at between 4% and 5. – Bloomberg

Article type: metered
User Type: anonymous web
User Status:
Campaign ID: 1
Cxense type: free
User access status: 3

Business , bayer , mosanto

   

Did you find this article insightful?

Yes
No

Next In Business News

AirAsia expects Choi to add value to its digital business devt in China
Ringgit stays flat amid lack of catalysts
Semicon and tech stocks rebound
Quick take: Dayang’s shares fall as 4Q profit slumps 83%
Quick take: Permaju shares jump 36% as it returns to black in 2Q
Kenanga maintains 'outperform' on DRB-Hicom
Trading ideas: Genting Plantations, DRB-Hicom, Inari, Aeon, Dayang, Destini
RHB stays bullish on Inari's prospects
Chinese banks, Australia's Macquarie tiptoe into Asian oil finance void
Australia's Afterpay to explore global listing as first-half sales double

Stories You'll Enjoy


Vouchers